Tetraphase Pharmaceuticals Shares Up 12.3% Premarket After Co. Received Positive CHMP Opinion For Xerava As Treatment For Complicated Intra-Abdominal Infections; European Commission Is Expected To Make Final Approval Decision Within Next Three Months